Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILIT with Preseasonal Booster in Grass Allergic Rhinitis
NCT04210193Phase 3Completed
- Start
- Apr 2014
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alutard-sq in allergic rhinitis (AR). Primary endpoints: Timothy specific IgG4 at 1 month and Timothy specific IgG4 at 9 months. Started Apr 2014; status: completed.
02
Drugs
alutard-sq
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04210193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210193.